This HTML5 document contains 58 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n18http://linked.opendata.cz/resource/drugbank/drug/DB00147/identifier/wikipedia/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00147/identifier/pharmgkb/
n10http://linked.opendata.cz/resource/mesh/concept/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00147/identifier/kegg-compound/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00147/identifier/pdb/
n8http://linked.opendata.cz/resource/drugbank/company/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00147/identifier/pubchem-compound/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00147/identifier/pubchem-substance/
n5http://bio2rdf.org/drugbank:
n13http://linked.opendata.cz/resource/drugbank/drug/DB00147/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n9http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00147/identifier/chemspider/
n7http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00147/identifier/chebi/

Statements

Subject Item
n2:DB00147
rdf:type
n3:Drug
n3:description
The 4-carboxyaldehyde form of vitamin B 6 which is converted to pyridoxal phosphate which is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. [PubChem]
n3:group
nutraceutical approved
n3:indication
Pyridoxal is one of the natural forms available of vitamin B6, therefore, it is used for nutritional supplementation and for treating dietary shortage or imbalances.
owl:sameAs
n5:DB00147 n6:DB00147
dcterms:title
Pyridoxal
adms:identifier
n12:1021 n13:DB00147 n14:17310 n15:1050 n16:PA164749166 n17:46506282 n18:Pyridoxal n19:C00250 n20:PXL
n3:mechanismOfAction
Pyridoxal is the precursor to pyridoxal phosphate. Pyridoxal 5'-phosphate is involved in a wide range of biochemical reactions, including the metabolism of amino acids and glycogen, the synthesis of nucleic acids, hemogloblin, sphingomyelin and other sphingolipids, and the synthesis of the neurotransmitters serotonin, dopamine, norepinephrine and gamma-aminobutyric acid (GABA).
n3:packager
n8:271B4B54-363D-11E5-9242-09173F13E4C5
n3:synonym
Pyridoxal 3-HYDROXY-5-(hydroxymethyl)-2-methylisonicotinaldehyde Pyridoxaldehyde
n3:toxicity
Oral LD<sub>50</sub> Rat: 2150 mg/kg, Oral LD<sub>50</sub> Mouse: 1800 mg/kg
n3:synthesisReference
Robert C. Siegel, "Synthesis of cross-links in the helical domain of collagen using pyridoxal 5-phosphate and copper or iron." U.S. Patent US4544638, issued June, 1981.
n9:hasConcept
n10:M0018240
n3:IUPAC-Name
n7:271B4B5A-363D-11E5-9242-09173F13E4C5
n3:InChI
n7:271B4B60-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n7:271B4B5F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B4B5C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n7:271B4B5D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n7:271B4B5E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n7:271B4B70-363D-11E5-9242-09173F13E4C5 n7:271B4B58-363D-11E5-9242-09173F13E4C5
n3:logP
n7:271B4B72-363D-11E5-9242-09173F13E4C5 n7:271B4B59-363D-11E5-9242-09173F13E4C5 n7:271B4B56-363D-11E5-9242-09173F13E4C5
n3:logS
n7:271B4B57-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n7:271B4B66-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n7:271B4B67-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n7:271B4B61-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n7:271B4B62-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n7:271B4B64-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n7:271B4B63-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n7:271B4B65-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
65-22-5
n3:category
n3:containedIn
n21:271B4B55-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n7:271B4B6C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n7:271B4B6E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n7:271B4B6F-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n7:271B4B71-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n7:271B4B6B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n7:271B4B6A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n7:271B4B6D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n7:271B4B5B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n7:271B4B68-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n7:271B4B69-363D-11E5-9242-09173F13E4C5